Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Hepatocellular Carcinoma Treatment Market 2021-2025

Published by TechNavio (Infiniti Research Ltd.) Product code 991122
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hepatocellular Carcinoma Treatment Market 2021-2025
Published: February 18, 2021 Content info: 120 Pages
Description

Global Hepatocellular Carcinoma Drugs Market 2021-2025

Technavio has been monitoring the hepatocellular carcinoma drugs market and it is poised to grow by $ 106.48 million during 2021-2025, progressing at a 4.10% during the forecast period. Our report on hepatocellular carcinoma drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of liver diseases and lifestyle diseases and growing prevalence of lifestyle diseases. In addition, growing prevalence of lifestyle diseases is anticipated to boost the growth of the market as well.

The hepatocellular carcinoma drugs market analysis includes the therapy segment and geographic landscape.

Technavio's hepatocellular carcinoma drugs market is segmented as below:

By Therapy

  • Chemotherapy
  • Brachytherapy
  • Ablation therapy

By Geographical Landscapes

  • North America
  • Europe
  • APAC
  • ROW

This study identifies the increasing product launches as one of the prime reasons driving the hepatocellular carcinoma drug market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on hepatocellular carcinoma drugs market covers the following areas:

  • Hepatocellular carcinoma drugs market sizing
  • Hepatocellular carcinoma drugs market forecast
  • Hepatocellular carcinoma drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatocellular carcinoma drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, and Pfizer Inc. Also, the hepatocellular carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents
Product Code: IRTNTR44339

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Therapy

  • Market segments
  • Comparison by Therapy
  • Chemotherapy - Market size and forecast 2019-2024
  • Brachytherapy - Market size and forecast 2019-2024
  • Ablation therapy - Market size and forecast 2019-2024
  • Market opportunity by Therapy

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Chemotherapy - Market size and forecast 2020-2025 ($ million)
  • 24: Chemotherapy - Year-over-year growth 2020-2025 (%)
  • 25: Brachytherapy - Market size and forecast 2020-2025 ($ million)
  • 26: Brachytherapy - Year-over-year growth 2020-2025 (%)
  • 27: Ablation therapy - Market size and forecast 2020-2025 ($ million)
  • 28: Ablation therapy - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AbbVie Inc. - Overview
  • 50: AbbVie Inc. - Business segments
  • 51: AbbVie Inc. - Key offerings
  • 52: AbbVie Inc. - Key customers
  • 53: AbbVie Inc. - Segment focus
  • 54: Amgen Inc. - Overview
  • 55: Amgen Inc. - Business segments
  • 56: Amgen Inc. - Key offerings
  • 57: Amgen Inc. - Key customers
  • 58: Amgen Inc. - Segment focus
  • 59: AstraZeneca Plc - Overview
  • 60: AstraZeneca Plc - Product and service
  • 61: AstraZeneca Plc - Key offerings
  • 62: AstraZeneca Plc - Key customers
  • 63: AstraZeneca Plc - Segment focus
  • 64: Bayer AG - Overview
  • 65: Bayer AG - Business segments
  • 66: Bayer AG - Key offerings
  • 67: Bayer AG - Key customers
  • 68: Bayer AG - Segment focus
  • 69: Bristol-Myers Squibb Co. - Overview
  • 70: Bristol-Myers Squibb Co. - Product and service
  • 71: Bristol-Myers Squibb Co. - Key offerings
  • 72: Bristol-Myers Squibb Co. - Key customers
  • 73: Bristol-Myers Squibb Co. - Segment focus
  • 74: Eli Lilly and Co. - Overview
  • 75: Eli Lilly and Co. - Business segments
  • 76: Eli Lilly and Co. - Key offerings
  • 77: Eli Lilly and Co. - Key customers
  • 78: Eli Lilly and Co. - Segment focus
  • 79: F. Hoffmann-La Roche Ltd. - Overview
  • 80: F. Hoffmann-La Roche Ltd. - Business segments
  • 81: F. Hoffmann-La Roche Ltd. - Key offerings
  • 82: F. Hoffmann-La Roche Ltd. - Key customers
  • 83: F. Hoffmann-La Roche Ltd. - Segment focus
  • 84: Gilead Sciences Inc. - Overview
  • 85: Gilead Sciences Inc. - Product and service
  • 86: Gilead Sciences Inc. - Key offerings
  • 87: Gilead Sciences Inc. - Key customers
  • 88: Gilead Sciences Inc. - Segment focus
  • 89: Johnson & Johnson - Overview
  • 90: Johnson & Johnson - Business segments
  • 91: Johnson & Johnson - Key offerings
  • 92: Johnson & Johnson - Key customers
  • 93: Johnson & Johnson - Segment focus
  • 94: Pfizer Inc. - Overview
  • 95: Pfizer Inc. - Business segments
  • 96: Pfizer Inc. - Key offerings
  • 97: Pfizer Inc. - Key customers
  • 98: Pfizer Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations
Back to Top